News for Tonix Pharmaceuticals Holding Corp. (TNXP)

**media[653948]**

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Thursday. Shares of Oxford Industries, Inc. OXM fell sharply i...

Creative Global Technology Holdings Limited (CGTL) is up over 54 percent in Thursday's pre-market trading. The following are some of the other stocks making big moves in Thursday's pre-market trading.

Tonix Pharmaceuticals (TNXP) to present at the 2025 BIO International Convention in Boston on June 16, 2025. FDA review of TNX-102 SL for fibromyalgia with

CHATHAM, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. ( TNXP) (Tonix or the Company), a fully-integrated biotechnology company

**media[650499]**

**media[646602]**

Alliance Global Partners has increased its price target for Tonix Pharmaceuticals (TNXP) from $11 to $65, while maintaining a Buy rating on the shares. This dec

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. ( TNXP), a fully-integrated biotechnology company with marketed products a

Tonix Pharmaceuticals (TNXP) has initiated dosing in the Phase 2 OASIS trial, which aims to assess the effectiveness of TNX-102 SL in alleviating acute stress r

**media[632760]**

Texas-based TSS, Inc. (TSSI) is up over 43 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Tonix Pharmaceuticals Holding Corp (TNXP) has appointed Joseph Hand, Esq. as its new General Counsel and Executive Vice President of Operations. This change is

**media[625360]**

Revenue: Reported at $2.4 million for Q1 2025, slightly below the estimated $2.55 million.Earnings Per Share (EPS): Recorded a net loss of $2.84 per share, out

FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating

Tonix Pharmaceuticals (TNXP) reported a net loss of $16.8 million ($2.84 per share) for Q1 2025. The PDUFA date for TNX-102 SL, a new fi

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cell

Tonix Pharmaceuticals (TNXP) recently unveiled promising findings at the American Association for Cancer Research's 2025 Annual Meeting in Chicago. The focus of